Loading…
← CockpitCompetitor Analysis › ANRO Alto Neuroscience, Inc.Open in the cockpit ↗

Alto Neuroscience, Inc.ANROCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Uses biomarker-based patient selection to develop precision psychiatric drugs matched to specific patient subtypes.

Momentum neutral 57
Mkt cap
$1.04B
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$16.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 12.2%
Hurdle
n/a
no reverse DCF
Next earnings
126 days
24 Mar 2027
Close · USD$25.91
1D+4.0%
1W-16.8%
1M+6.2%
3M-24.4%
6M+24.7%
YTD+45.6%
1Y+87.8%
ATR %8.2%
Beta1.71
52w lowhigh30.9% off high

What Alto Neuroscience does

Uses biomarker-based patient selection to develop precision psychiatric drugs matched to specific patient subtypes.

Pre-revenue: it sells nothing, and trial costs are paid from cash raised since its early-2024 listing. Each drug is tested only in patients whose brain-activity or other markers match, so the results of those mid-stage depression trials, not sales, decide the company's course.

Products and services

  • ALTO-100 (major depressive disorder)
  • ALTO-300 (biomarker-selected depression)

Customers

  • Psychiatrists (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Precision psychiatry drug development

What could go right

  • Improved trial success odds via biomarker selection
  • Large underserved psychiatric drug market

What could go wrong

  • Clinical trial failure risk
  • Unproven biomarker-selection approach at scale

Moat: narrow (data, process know-how). Proprietary biomarker/EEG-based patient stratification aims to improve historically poor psychiatric trial success rates.

Headquarters: Los Altos, California, US · Founded: 2019 · Employees: 68

Named competitors

Alto Neuroscience at a glance

Size Alto Neuroscience (ANRO) is a United States Health Care company (Biotechnology) with a market value of $1.04B, the 2208th largest of 3,085 United States companies the cockpit tracks. Shares closed at $25.91 on 18 Nov 2026.

Performance Over six months the shares gained 24.7%, against -16.6% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.

Short interest Short interest is 14.5% of the free float (30 Oct 2026).

Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026ANRO 120Peer median 83
Six months, rebased to 100: Alto Neuroscience against the median of its 20 peers (local-currency closes).

Alto Neuroscience financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$641,000-$661,000-$502,000-$373,000-$342,000
EBITDA-$99.5M-$65.7M-$68.1M-$37.4M-$28.9M
Net income-$95.2M-$63.2M-$61.4M-$36.3M-$27.7M
Free cash flow-$79.7M-$51.8M-$49.5M-$33.9M-$21.1M
Capital expenditure$556,000$24,000$2.08M$470,000$732,000
Total debt$18.0M$24.0M$16.9M$151M$82.1M

Quarterly statements and history in the cockpit →

Alto Neuroscience competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-40%-20%0%300482002030INBX9606JBIOSGP688276VORCMPS600195688253ODTX2160AKUMSMLYS6887394587ANRO6-month return →1-month return →
Up and to the right = strong over both horizons. Alto Neuroscience is the large dot.

Alto Neuroscience competitors and peer comparison

Head to head with its named competitors (ANRO vs NBIX)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Alto Neuroscience ANRO$1.04B+25%n/an/an/an/a
Neurocrine Biosciences NBIX$16.5B+5%+38%25%4.4×-1.5%

How Alto Neuroscience compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Alto Neuroscience against its 20 peers (data as of 18 Nov 2026)
MeasureANROPeer medianRank in peer set
1-month return+6.2%-8.6%2nd highest of 21
6-month return+24.7%-16.6%3rd highest of 20
Distance from 52-week high-30.9%-40.8%5th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Alto Neuroscience ANROUnited States$1.04B+25%n/an/an/an/an/a
Guangzhou Wondfo Biotech 300482.SZChina$1.05B-18%-24%-2%2.9×14.3%-5.8%
Daan Gene 002030.SZChina$1.05B-17%+1%-81%8.0×4.8%-32.3%
Inhibrx Biosciences INBXUnited States$1.02B-37%+43%-6,287%551.0×n/an/a
Duality Biotherapeutics 9606.HKHong Kong$1.06B-58%-5%-181%5.6×n/an/a
Jade Biosciences JBIOUnited States$1.07B-34%n/an/an/an/an/a
SpyGlass Pharma SGPUnited States$993M+36%n/an/an/an/an/a
Changchun BCHT Biotechnology 688276.SSChina$992M-2%+2%-29%9.9×n/an/a
Vor Biopharma VORUnited States$1.10B+15%n/an/an/an/an/a
COMPASS Pathways Plc Sponsored ADR CMPSUnited States$1.15B-25%n/an/an/an/an/a
Kardigan KARDUnited States$1.15Bn/an/an/an/an/an/a
China Animal Husbandry Industry 600195.SSChina$921M-16%+1%2%1.3×6.1%+4.4%
Innovita Biological Technology 688253.SSChina$915M-28%-28%11%14.0×39.6%-16.6%
Odyssey Therapeutics ODTXUnited States$912M+12%-33%-5,415%204.9×n/an/a
Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZChina$909M-15%0%22%4.2×9.2%+2.3%
GNI 2160.TJapan$903M-25%+44%-21%6.2×n/an/a
Akums Drugs and Pharmaceuticals AKUMS.NSIndia$1.21B+38%+18%10%2.0×15.3%+9.9%
Mineralys Therapeutics MLYSUnited States$1.22B-52%n/an/an/an/an/a
Liaoning Chengda Biotechnology 688739.SSChina$1.22B-14%-9%0%2.2×6.6%-7.0%
Peptidream 4587.TJapan$878M-3%+14%-18%6.6×n/an/a
Pacific Shuanglin Bio-pharmacy 000403.SZChina$1.24B-21%+1%10%3.5×n/an/a

Questions

Who are Alto Neuroscience's main competitors?
Named competitors: Sage Therapeutics (private or unlisted), Neurocrine Biosciences (NBIX). The cockpit's measured peer set (industry) also includes Guangzhou Wondfo Biotech (300482.SZ), Daan Gene (002030.SZ), Inhibrx Biosciences (INBX), Duality Biotherapeutics (9606.HK), Jade Biosciences (JBIO), SpyGlass Pharma (SGP).
How has Alto Neuroscience stock performed?
Over six months to 18 Nov 2026 the shares returned +24.7% against -16.6% for the median peer; over one year +87.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.